Market Analysis: Global Autoimmune Hemolytic Anemia Treatment Market
Autoimmune hemolytic anemia Treatment Market is growing at a steady CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth
Market Definition: Global Autoimmune Hemolytic Anemia Treatment Market
Autoimmune Hemolytic Anemia is also known as idiopathic autoimmune hemolytic is defined as rare, autoimmune disorders in which various types of auto-antibodies are directed against red blood cells. It occurs when immune system dysfunction and start produces auto-antibodies, which destroy red blood cells at faster rate before there life span over. Destruction of red blood cells results in severe complications including anemia, leading to weakness and fatigue.
According to the statistics published in the Orphanet, an estimated annual incidence of autoimmune hemolytic anemia is 1 in 35,000-80,000 in the North America and Western Europe. Huge financial support from the government and increase demand of novel treatment are key factors for market growth
Get More Insights About Global Autoimmune Hemolytic Anemia Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autoimmune-hemolytic-anemia-treatment-market
The emergence of drugs such as penicillin, antimalarial medicines, sulfa medicines and acetaminophen for treating chronic conditions as these drugs can induce hemolytic anemia is act as drivers for market growth
Prevalence of certain tumors and autoimmune disorders can increase the risk of hemolytic anemia is accelerating the market growth
Huge financial support to the researchers for developing novel intervention is enhancing the market growth
High specific demand of novel treatment is propelling the market growth
Lack of trained personnel and stringent safety regulations is hampering the market growth
Limited availability of specific medicinal treatment options due to low prevalence of hemolytic anemia is restraining the market growth
Segmentation: Global Autoimmune Hemolytic Anemia Treatment Market
Warm Autoimmune Induced Hemolytic Anemia
Cold Agglutinin Disease (CAD)
By Therapy Type
First Line Therapy
Second Line Therapy
Third Line Therapy
By Route of Administration
By End Users
Rest of South America
Rest of Europe
Rest of Asia Pacific
Middle East & Africa
Rest of Middle East & Africa
Know more about this report https://www.databridgemarketresearch.com/reports/global-autoimmune-hemolytic-anemia-treatment-market
Key Developments in the Market:
In August 2019, Momenta Pharmaceuticals, Inc initiated phase II/III trial for Nipocalimab (M281), an FcRn inhibitor to be developed for the treatment of warm Autoimmune Hemolytic Anemia (wAIHA). It is also received Fast Tract designation from the FDA for Nipocalimab. The Fast-Track designation accelerates review timelines and enhances the interaction with the FDA, which can bring drug to the patients as quickly as possible.
In June 2019, Apellis Pharmaceuticals presented a data for its phase II (PLAUDIT study) of APL-2 at the 24th Annual Congress of the European Hematology Association (EHA), the Netherlands. The trial has demonstrated improvements in hematologic measures in patients with utoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Seeing the potential promising results of their upcoming novel C3 inhibitor will help the patients with autoimmune hemolytic anemia throughout the world.
Global autoimmune hemolytic anemia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Global autoimmune hemolytic anemia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
Few of the major competitors currently working in the autoimmune hemolytic anemia treatment market are Momenta Pharmaceuticals, Inc, Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Vertice Pharma, Concord Biotech, Alkem Labs, Dr. Reddy’s Laboratories Ltd, Jubilant Life Sciences Ltd, Strides Pharma Science Limited, Mylan N.V., Novartis AG, Sanofi, Rigel Pharmaceuticals Inc, Incyte Corporation, Alexion Pharmaceuticals, Inc and others
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-autoimmune-hemolytic-anemia-treatment-market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market